Amneal launches first biosimilar with Alymsys
BRIDGEWATER, N.J. — Amneal Pharmaceuticals announced the commercial launch of Alymsys (bevacizumab-maly), a biosimilar referencing Avastin. Alymsys is a vascular endothelial growth factor inhibitor used in oncology. This product was developed by mAbxience, a global biotech company with over a decade of experience in the development, manufacture, and commercialization of biopharmaceuticals. “The launch of Alymsys
